Appointments

866.320.4573

Request an Appointment

Questions

800.223.2273

Contact us with Questions

Expand Content

Manmeet Ahluwalia, MD

216.636.0007

Manmeet Ahluwalia, MD
Department: Brain Tumor and Neuro-Oncology Center
Location: Cleveland Clinic Main Campus
Mail Code S73
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.636.0007
WorkFax:216.444.0924
Manmeet Ahluwalia, MD
Department: Hematology and Oncology
Location: Cleveland Clinic Main Campus
Mail Code S73
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.636.0007
WorkFax:216.444.0924
Surgeon:
No
Treats:
Adults Only

Biographical Sketch

Manmeet Ahluwalia, MD, FACP is an Associate Professor in the Department of Medicine, Clinic Lerner College of Medicine of Case Western Reserve University (CCLCM) where he subspecializes in treatment of patients with brain tumors and brain metastases. He is the Director, Brain Metastasis Research Program and the Associate Director, Clinical Trials, Operations in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center of the Neurological Institute of Cleveland Clinic. He is the Section Head of NeuroOncology Outcomes and is a staff in the Taussig Cancer Institute, Cleveland Clinic and has joint appointment in the Developmental Therapeutics Program, Case Comprehensive Cancer Center.

Dr. Ahluwalia's research focuses on the development of new therapies for patients with brain tumors and brain metastases. He is currently leading several clinical trials involving new targeted therapies as well as treatments targeting tumor blood vessels (angiogenesis) and cancer stem cells. His results have been presented nationally and internationally and have resulted in over 70 editorials, peer-reviewed manuscripts and book chapters. Dr. Ahluwalia serves as the Associate Editor on Tumor Section of Neurosurgery, the official Journal of Congress of Neurological Surgeons (CNS). He is the Associate Editor of ASCO Post, the newsletter of ASCO. He is the Section Editor of NeuroOncology for HemOnc Today. He serves as a reviewer on multiple journals including Cancer, NeuroOncology, Cancer Research, Journal of NeuroOncology, Expert Reviews in Neurotherapeutics, BMC Cancer, Molecular Cancer Research, Expert Review of Anticancer Therapy, Expert Opinion in Pharmacotherapy, Journal of Neurology & Neurophysiology.

Dr. Ahluwalia received his MD degree from the Maulana Azad Medical College, University of Delhi. He completed his residency at Fairview General Hospital and fellowship training at the Roswell Park Cancer Institute.

Professional Highlights

  • Chair, Education Committee of the Central Nervous System (CNS) track of American Society of Clinical Oncology (ASCO), 2014-15
  • Chair of the Membership Committee of Society for Neuro-Oncology (SNO)
  • Diplomate, United Council for Neurologic Subspecialties- Neuro-Oncology, 2013
  • Fellowship, American College of Physicians, 2012
  • Methods in Clinical Cancer Research Award, ASCO/AACR, August 2010
  • Diplomate, Oncology, American Board of Internal Medicine, 2009
  • Diplomate, Hematology, American Board of Internal Medicine, 2009
  • Diplomate, American Board of Internal Medicine, 2006

Education & Fellowships

Fellowship - Roswell Park Cancer Institute
Medical Oncology-Hematology
Buffalo, NY USA
2009
Residency - Fairview General Hospital
Internal Medicine
Cleveland, OH USA
2006
Medical School - Maulana Azad Medical College, University of Delhi
New Delhi India
2000

Certifications

  • Internal Medicine
  • Internal Medicine- Medical Oncology
  • Internal Medicine- Hematology

Specialty Interests

benign and malignant tumors of the brain and spinal cord, benign brain tumors (meningiomas, schwannomas), Brain Metastases, brain tumors, experimental therapeutics, molecular biology of brain tumors clinical and translational trials, neuro-oncology

Awards & Honors

  • Marquis Who's Who in America, 2014
  • US News and Castle Connolly's Top Doctor, 2012
  • Methods in Clinical Cancer Research Award, ASCO/AACR, August 2010
  • Best Research Award: Basic Science Project, Roswell Park Cancer Institute, Buffalo, New York, June 2009
  • Named in Strathmore’s Who’s Who, 2008-09
  • Sigma Xi Research Society, 2008
  • Outstanding Intern Award, Fairview Hospital, Cleveland Clinic Health

Treatment & Services

  • Brain Tumor Diagnosis
  • Brain Tumor Management
  • Chemotherapy
  • Clinical Trials
  • Experimental Therapeutics
  • Neuro-Oncology

Specialty in Diseases and Conditions

  • Adult Brain Tumors
  • Anaplastic Astrocytomas
  • Anaplastic Oligodendrogliomas
  • Astrocytoma
  • Benign Brain Tumors
  • Benign Tumors of the Brain
  • Benign Tumors of the Spinal Cord
  • Brain Cancer (Brain Tumor)
  • Brain Lymphoma
  • Brain Metastases
  • Chordomas
  • Clival Chordomas
  • Ependymomas
  • Glioblastoma Multiforme
  • Malignant Gliomas
  • Malignant Tumors of the Brain
  • Malignant Tumors of the Spinal Cord
  • Meningioma
  • Metastatic Cancer
  • Oligodendroglioma
  • Primary Central Nervous System Lymphomas
  • Sarcomas of the Brain or Head
  • Schwannoma

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 12/16/2014, Dr. Ahluwalia has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Ahluwalia receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Monteris Medical, Inc.
  • PrIME Oncology, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English